Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression

  1. Erik S. Knudsen1,2,3,4,5,
  2. Carolan Buckmaster2,3,5,
  3. Tung-Ti Chen1,4,5,
  4. James R. Feramisco2,3,5, and
  5. Jean Y.J. Wang1,4,5,6
  1. Departments of 1Biology, 2Medicine, and 3Pharmacology, 4Center for Molecular Genetics, 5Cancer Center, University of California, San Diego (UCSD), La Jolla, California 92093-0322 USA

Abstract

The retinoblastoma tumor suppressor protein, RB, is a negative regulator of cell proliferation. Growth inhibitory activity of RB is attenuated by phosphorylation. Mutation of a combination of phosphorylation sites leads to a constitutively active RB. In Rat-1 cells, the phosphorylation-site-mutated (PSM)-RB, but not wild-type RB, can inhibit S-phase entry. In PSM-RB-arrested G1 cells, normal levels of cyclin E and cyclin E-associated kinase activity were detected, but the expression of cyclin A was inhibited. The ectopic expression of cyclin E restored cyclin A expression and drove the PSM-RB expressing cells into S phase. Interestingly, Rat-1 cells coexpressing cyclin E and PSM-RB could not complete DNA replication. Microinjection of cells that have passed through the G1restriction point with plasmids expressing PSM-RB also led to the inhibition of DNA synthesis. The S-phase inhibitory activity of PSM-RB could be attenuated by the coinjection of SV40 T-antigen, adenovirus E1A, or a high level of E2F-1 expression plasmids. However, the S-phase inhibitory activity of PSM-RB could not be overcome by the coinjection of cyclin E or cyclin A expression plasmids. These results reveal a novel role for RB in the inhibition of S-phase progression that is distinct from the inhibition of the G1/S transition, and suggest that continued phosphorylation of RB beyond G1/S is required for the completion of DNA replication.

Keywords

Footnotes

  • 6 Corresponding author.

  • E-MAIL jywang{at}ucsd.edu FAX (619) 534-2821.

    • Received February 5, 1998.
    • Accepted May 27, 1998.
| Table of Contents

Life Science Alliance